Latest filing published 22 Oct 2026 for CSPC Pharmaceutical Group Ltd..
Based on 48 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Cai Dong Chen is a large-scale open-market buyer at CSPC Pharmaceutical Group Ltd., listed in Hong Kong: 51 purchases, 48 of them with an amount, worth EUR 244.1 million with a median of EUR 2,161,703. Buying makes up 94% of market trades. The largest amounts are EUR 45,684,240 on March 26, 2026, EUR 30,970,874 on May 28, 2026 and EUR 24,656,968 on November 21, 2025.
On the selling side, 3 sales are recorded, 2 of them with an amount, worth EUR 66.3 million: EUR 66,080,998 on November 17, 2017 and EUR 236,517 on May 30, 2022.
The stored past results of the purchases, on 48 trades at 90 days, give a median of 7.2%, with 67% of results positive: stored past results, not a forecast.
The record counts 72 filings since November 2017, 18 of them of another nature. Activity accelerates: 16 filings in 2024 and 21 in 2025, against 1 in 2019. Over the last twelve months, 13 filings were published, 10 of them purchases. Publication comes a median of 1 day after the trade. 13, 7 and 7 trades by Chen fall within 30 days of colleagues at CSPC Pharmaceutical Group Ltd., in that order. In the same direction: 8, 7 and 2. Colleagues in order: Zhang Cuilong, Jiang Hao and Li Chunlei.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 73 declarations